NASDAQ:VRCAVerrica Pharmaceuticals Stock Price, Forecast & News

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VRCA stock has increased by 9.0% and is now trading at $11.47. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Verrica Pharmaceuticals.

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Verrica Pharmaceuticals.

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) announced its earnings results on Thursday, May, 7th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.01. View Verrica Pharmaceuticals' earnings history.

2 equities research analysts have issued 12-month price targets for Verrica Pharmaceuticals' shares. Their forecasts range from $20.00 to $24.00. On average, they expect Verrica Pharmaceuticals' share price to reach $22.00 in the next year. This suggests a possible upside of 91.8% from the stock's current price. View analysts' price targets for Verrica Pharmaceuticals.

News coverage about VRCA stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutVerrica Pharmaceuticals.

Verrica Pharmaceuticals saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 754,900 shares, a drop of 5.3% from the April 15th total of 797,100 shares. Based on an average daily volume of 67,900 shares, the days-to-cover ratio is presently 11.1 days. Currently, 5.9% of the company's stock are short sold. View Verrica Pharmaceuticals' Current Options Chain.

Some companies that are related to Verrica Pharmaceuticals include ZEALAND PHARMA/S (ZEAL), Innoviva (INVA), Portola Pharmaceuticals (PTLA), Phoenix Tree (IMAB), Intra-Cellular Therapies (ITCI), Karyopharm Therapeutics (KPTI), Tricida (TCDA), Phathom Pharmaceuticals (PHAT), Supernus Pharmaceuticals (SUPN), Revance Therapeutics (RVNC), Arcus Biosciences (RCUS), Cytokinetics (CYTK), Kiniksa Pharmaceuticals (KNSA), I-Mab (ARQT) and MacroGenics (MGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include AbbVie (ABBV), Gilead Sciences (GILD), Aurora Cannabis (ACB), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Pfizer (PFE), Progenics Pharmaceuticals (PGNX), Exxon Mobil (XOM), Allergan (AGN) and Agile Therapeutics (AGRX).

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Verrica Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.82%), Kornitzer Capital Management Inc. KS (1.82%), Fosun International Ltd (1.26%), State Street Corp (0.91%), Geode Capital Management LLC (0.70%) and Nuveen Asset Management LLC (0.20%). Company insiders that own Verrica Pharmaceuticals stock include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White. View institutional ownership trends for Verrica Pharmaceuticals.

VRCA stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Morgan Stanley, Squarepoint Ops LLC, Wells Fargo & Company MN, and UBS Group AG. View insider buying and selling activity for Verrica Pharmaceuticals.

VRCA stock was acquired by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., State Street Corp, Nuveen Asset Management LLC, Alliancebernstein L.P., BlackRock Inc., and Capital Investment Advisory Services LLC. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning, Sean Stalfort, and Ted White. View insider buying and selling activity for Verrica Pharmaceuticals.

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRCA stock can currently be purchased for approximately $11.47.

Verrica Pharmaceuticals has a market capitalization of $296.04 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.

The official website for Verrica Pharmaceuticals is www.verrica.com.

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]